Invest now

Remus Pharmaceuticals share price

  • NaN%Low risk
  • NaN%Moderate risk
  • NaN%Balanced risk
  • NaN%High risk
  • NaN%Extreme risk
  • ₹816.00(0.12%)
    November 9, 2026 14:45:30 PM IST
    • NSE
    • BSE
  • Vol : 1.40 K (NSE + BSE)
    Last 20 day avg : 6.74 K
Remus Pharmaceuticals is trading 0.12% upper at Rs 816.00 as compared to its last closing price. Remus Pharmaceuticals has been trading in the price range of 820.00 & 782.00. Remus Pharmaceuticals has given 13.99% in this year & -5.09% in the last 5 days. Remus Pharmaceuticals has TTM P/E ratio 21.60 as compared to the sector P/E of 30.23.The company posted a net profit of 21.77 Crores in its last quarter.Listed peers of Remus Pharmaceuticals include Sun Pharmaceutical Industries (-0.50%), Divi's Laboratories (4.01%), Torrent Pharmaceuticals (-0.77%).The Mutual Fund holding in Remus Pharmaceuticals was at -% in . The MF holding has - from the last quarter. The FII holding in Remus Pharmaceuticals was at 5.10% in 30 Sep 2026. The FII holding has decreased from the last quarter.
  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Loading...
Key Metrics

Updated on 09 Nov 2026, 03:01 PM IST

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.28
    High volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.08
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.12
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    0.39
    Indicates undervaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
782.00
Highest
820.00
52 week range
Lowest
580.00
Highest
1,039.00
Remus Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
1,905.45-0.504,57,170.5138.405.550.830.47
Divi's Laboratories
11,525.004.013,05,952.5373.3211.480.410.03
Torrent Pharmaceuticals
4,734.40-0.771,80,074.9172.7319.220.80141.16
Cipla
1,402.85-0.571,13,330.4227.573.330.921.11
Zydus Lifesciences
1,210.950.911,20,792.7321.194.240.0914.22
Remus Pharmaceuticals Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-11-03Quarterly Results, Dividend and Other business matters
2026-05-20Audited Results, Dividend & Others
2025-11-10Quarterly Results & Interim Dividend
2025-05-17Audited Results, Dividend & Others
2024-11-09Quarterly Results & Interim Dividend
About the company Remus Pharmaceuticals
  • IndustryBiotechnology & Drugs
  • ISININE0O5T01011
  • BSE Code
  • NSE CodeREMUS
Remus Pharmaceuticals Limited is an India-based company, which is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. The Company also deals in active pharmaceutical ingredients (APIs). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. It offers a range of pharmaceutical formulations and products manufactured on contract manufacturing and on a loan license basis. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension and tablet. The Company offers its products in various therapeutic categories, such as oncology, cardiovascular, anti-diabetic, central nervous system (CNS), immunosuppressants, anti-biotic - antibacterial and dermatology.
  • Management Info
  • Anjali ShahChief Financial Officer
  • Deval PatelCompliance Officer, Company Secretary
  • Arpit ShahManaging Director, Executive Director
  • Roma ShahWhole Time Director
Remus Pharmaceuticals Share Price FAQs

Remus Pharmaceuticals is trading at 816.00 as on Mon Nov 09 2026 09:15:30. This is 0.12% upper as compared to its previous closing price of 839.80.

The market capitalization of Remus Pharmaceuticals is 961.57 Cr as on Mon Nov 09 2026 09:15:30.

The 52 wk high for Remus Pharmaceuticals is 1039.00 whereas the 52 wk low is 580.00

Remus Pharmaceuticals can be analyzed on the following key metrics -

  • TTM P/E: 21.60
  • Sector P/E: 30.23
  • Dividend Yield: 0.19%
  • D/E ratio: 0.05

Remus Pharmaceuticals reported a net profit of 36.99 Cr in 2026.